Last reviewed · How we verify
MECLIZINE HYDROCHLORIDE
At a glance
| Generic name | MECLIZINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1957 |
Approved indications
Common side effects
- Drowsiness
- Dry mouth
- Headache
- Fatigue
- Vomiting
- Anaphylactic reaction
- Blurred vision
Serious adverse events
- Anaphylactic reaction
Key clinical trials
- Motion Sickness Medications and Vestibular Time Constant (PHASE4)
- Meclizine for Hepatocellular Carcinoma (PHASE1)
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance (PHASE2)
- Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin (PHASE3)
- Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers (PHASE1, PHASE2)
- Meclizine Plasma Levels in Responders and Non-responders (PHASE4)
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MECLIZINE HYDROCHLORIDE CI brief — competitive landscape report
- MECLIZINE HYDROCHLORIDE updates RSS · CI watch RSS